Loading the session
Loading the session
Loading instrument
$4.71
+1.07%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:12 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
28.7M shares were sold short at the 15 Oct 2026 settlement, 14.0% of the 205.5M shares outstanding; covering them would take 12.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: +0.2% (SPY −1.6%). 3 months: −15.4% (SPY −0.4%). 1 year: +12.8% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SVRA, SPY · as of 4 Nov 2026
The 4 Nov 2026 close of $4.66 was 7.2% below its 50-day average ($5.02) and 13.3% below its 200-day average ($5.37). It has closed below the 200-day for 49 sessions, since 27 Aug 2026. The 50-day average crossed below the 200-day on 11 Sep 2026, 38 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $4.66 on 4 Nov 2026: 33.5% below the 52-week high of $7.01 (12 Dec 2025) and 20.7% above the low of $3.86 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
November 28, 2025
+17.35%May 27, 2025
−31.69%June 30, 2023
+18.33%